Study looks at cholesterol Rx publicity

Voluminous press coverage over cholesterol drug safety has led to a study measuring consumer perception. “Impact of Publicity on Consumer Perceptions and Actions in the Cholesterol Medication Category,” by Phoenix Marketing International, surveyed 601 high cholesterol sufferers; 75% taking meds. 

The study found that heightened publicity awareness led to “triple the number of consumers…asking to switch medications if they are aware of the publicity,” according to an executive summary. “The most remembered topics [among participants] questioned the benefits of lowering cholesterol as well as the efficacy of available medications in general,” said Beth Allen, EVP, marketing sciences at Phoenix. “The one topic that caused the most people to want to stop their medications or switch was about executives keeping bad news hidden. These findings suggest that people who need to medically control their cholesterol may be losing their trust in the pharmaceutical industry, their medications and need to treat this life-threatening disease.”

Reports on Vytorin, Zetia and the ENHANCE trials were followed by criticism about Pfizer's marketing of Lipitor. 
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.